Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Showing 1111 results
June 2023
-
Media ReleaseNovartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroupsKisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of…
-
Media ReleaseNovartis receives European approval for Cosentyx® as first and only IL-17A inhibitor for hidradenitis suppurativaCosentyx® (secukinumab) is the first new biologic treatment for hidradenitis suppurativa (HS) in nearly a decade, offering clinically meaningful results across the most debilitating symptoms1,…
-
Media ReleaseSandoz plans move to new central Basel headquarters by mid-2024, following proposed spin-off as standalone companySandoz AG to remain based in Basel, Switzerland following proposed spin-off from Novartis Announcement of planned city-center HQ marks important milestone as Sandoz prepares to become independent…
May 2023
-
Media ReleaseSandoz Marketing Authorization Applications for proposed biosimilar denosumab accepted by EMASubmissions supported by comprehensive analytical and clinical data package including a Phase I PK/PD similarity study and the integrated Phase I/III ROSALIA clinical trialDenosumab is indicated for…
-
Media ReleaseNew Sandoz Board of Directors appointedNovartis Board of Directors approves the recommendation of Sandoz Chairman-designate for the future Sandoz Board of Directors, to start preparatory work in June, followed by formal constitution in H2…
-
Media ReleaseNovartis to feature new PNH and CML scientific data from broad hematology portfolio at European Hematology Association Annual MeetingUpdated iptacopan data confirm hemolysis control in paroxysmal nocturnal hemoglobinuria (PNH) patients from Phase III APPLY-PNH and APPOINT-PNH studiesHead-to-head data from Phase III ASCEMBL trial…
-
Media ReleaseSandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilarsSandoz and Just - Evotec Biologics announce partnership to develop and manufacture multiple biosimilars with an option for expansionSandoz gains access to proprietary AI-driven technology platform…
-
Media ReleaseSandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicinesAgreement offers exclusive rights to commercialize six products in key areas of anti-infectives and oncology.Products from Adalvo slated for near- to mid-term launches, with four out of six…
April 2023
-
Media ReleaseNovartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativaPositive opinion paves way for first new treatment option in hidradenitis suppurativa (HS) in nearly a decadeCommittee for Medicinal Products for Human Use (CHMP) opinion based on robust Phase III…
-
Media ReleaseNovartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCOPrimary analysis of NATALEE, the first and only positive Phase III study of a CDK4/6 inhibitor in a broad population of patients with stage II and III HR+/HER2- early breast cancer at risk of…
-
Media ReleaseNovartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patientsData at EBMT show primary endpoint met – estimated* 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2 g/dL or more hemoglobin-level increase from…
-
Key ReleaseNovartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidanceAd hoc announcement pursuant to Art. 53 LR Q1 sales grew +8% (cc1, +3% USD) and core operating income grew +15% (cc, +8% USD) Innovative Medicines (IM) sales grew +7% (cc, +3% USD) and core…